Fisher & Paykel hikes guidance for FY26 revenue, earnings
Make us a preferred source
Make us a preferred source on Google
The news: Healthcare equipment maker Fisher & Paykel has raised its full-year revenue and earnings guidance, as the company said it “continues to work through” implications of the US Supreme Court’s ruling on the country’s global trade tariffs.
The numbers: The company now expects full-year operating revenue to be NZD2.30 billion ($1.94 billion), up from previous guidance of NZD2.17-NZD2.27 billion. It is guiding for net profit after tax of NZD450-NZD470 million, up from its previous range of NZD410-NZD460 million.
The context: Fisher & Paykel said the new guidance does not incorporate any potential refund of US tariffs paid to during the 2026 financial year to date.
The company noted the US Supreme Court’s ruling to invalidated tariffs imposed by US President Donald Trump under the International Emergency Economic Powers Act, announced on Saturday morning AEDT.
However, it said there are “still a number of uncertainties” on what the decision means for companies that import into the US.
Fisher & Paykel said it “does not currently believe these matters have any material impact on the company’s long-term direction, strategy or sustainable profitable growth.”
What they said: “While relative seasonal respiratory hospitalisations in the Northern Hemisphere winter may continue to impact the second half result, our performance to date suggests pleasing progress in our efforts to change clinical practice,” said Fisher & Paykel’s managing director and CEO Lewis Gradon.
“Continuous improvement activities and other efficiency gains are also contributing to improvements in our gross margin and operating margin.”
The source: ASX
